Contineum Therapeutics, INC.(CTNM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CTNM Contineum Therapeutics, INC.

Pre-Market Trading 04-04 04:46:15 EDT

6.13

-0.65

-9.59%

High6.95	Low6.11	Vol87.63K
Open6.52	D1 Closing6.78	Amplitude12.39%
Mkt Cap158.02M	Tradable Cap80.95M	Total Shares25.78M
T/O551.30K	T/O Rate0.66%	Tradable Shares13.21M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"CTNM","market":"US","secType":"STK","nameCN":"Contineum Therapeutics, INC.","latestPrice":6.13,"timestamp":1743710400000,"preClose":6.78,"halted":0,"volume":87627,"delay":0,"floatShares":13205197,"shares":25777793,"eps":-2.144147,"marketStatus":"Pre-Market Trading","change":-0.65,"latestTime":"04-04 04:46:12 EDT","open":6.52,"high":6.95,"low":6.11,"amount":551301.5901660001,"amplitude":0.123894,"askPrice":9.74,"askSize":100,"bidPrice":2.86,"bidSize":75,"shortable":3,"etf":0,"ttmEps":-2.144147,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1743773400000},"marketStatusCode":1,"adr":0,"listingDate":1712289600000,"exchange":"NASDAQ","adjPreClose":6.13,"postHourTrading":{"tag":"盘后","latestPrice":6.13,"preClose":6.13,"latestTime":"17:54 EDT","volume":701,"amount":4294.13,"timestamp":1743717273254},"volumeRatio":2.059843999126201},"requestUrl":"/m/hq/s/CTNM/wiki","defaultTab":"wiki","newsList":[{"id":"2523843923","title":"Analysts Are Bullish on Top NA Stocks: Unusual Machines Inc. (UMAC), Contineum Therapeutics, Inc. Class A (CTNM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2523843923","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523843923?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 22:20","pubTimestamp":1743430809,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 3 analysts just weighed in on Unusual Machines Inc. (UMAC – Research Report), Contineum Th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-na-stocks-unusual-machines-inc-umac-contineum-therapeutics-inc-class-a-ctnm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-na-stocks-unusual-machines-inc-umac-contineum-therapeutics-inc-class-a-ctnm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTNM","BK4141","UMAC","BK4007","BK4157","NA","BK4603"],"gpt_icon":0},{"id":"2520686073","title":"Contineum Therapeutics Appoints Diego Miralles to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2520686073","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520686073?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 04:42","pubTimestamp":1742244169,"startTime":"0","endTime":"0","summary":"An update from Contineum Therapeutics, Inc. Class A ( ($CTNM) ) is now available. On March 14, 2025, Contineum Therapeutics, Inc. appointed Diego M...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/contineum-therapeutics-appoints-diego-miralles-to-board?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/contineum-therapeutics-appoints-diego-miralles-to-board?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CTNM","LENZ","BK4139","BK4007"],"gpt_icon":0},{"id":"2520688031","title":"Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2520688031","media":"Business Wire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520688031?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 04:05","pubTimestamp":1742241900,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 17, 2025----Contineum Therapeutics, Inc.  , a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology  indications, today announced the appointment of Diego Miralles, M.D. as a member of its board of directors, effective March 14, 2025.\"We are excited to welcome Diego to our board,\" commented Eef Schimmelpennink, Contineum’s Chairperson. \"He has successfully led the development of novel therapies throughout his distinguished career and has an extensive track record in both early stage research and all stages of clinical development. During his time at Janssen Research, Dr. Miralles was engaged in the development and approval of several important medicines. He is an accomplished life sciences executive and his perspective in guiding life sciences companies will provide our board with valuable insights as we look ahead to key clinical development and operating milestones.\". Contineum Ther","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/contineum-therapeutics-announces-appointment-diego-200500029.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTNM","BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2519785337","title":"Buy Rating for Contineum Therapeutics: Promising Pipeline and Market Opportunities","url":"https://stock-news.laohu8.com/highlight/detail?id=2519785337","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519785337?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 22:35","pubTimestamp":1741876532,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics, Inc. Class A (CTNM) has received a new Buy rating, initiated by JonesTrading analyst, Debanjana Chatterjee. Debanjana Chatt...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-contineum-therapeutics-promising-pipeline-and-market-opportunities?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-contineum-therapeutics-promising-pipeline-and-market-opportunities?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","CTNM"],"gpt_icon":0},{"id":"2519839647","title":"JonesTrading Initiates Contineum Therapeutics at Buy With $23 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2519839647","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519839647?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 20:47","pubTimestamp":1741870047,"startTime":"0","endTime":"0","summary":"JonesTrading Initiates Contineum Therapeutics at Buy With $23 Price Target","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","CTNM"],"gpt_icon":0},{"id":"2519483675","title":"Contineum Therapeutics Inc : Jonestrading Initiates Coverage With Buy Rating; Price Target $23","url":"https://stock-news.laohu8.com/highlight/detail?id=2519483675","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519483675?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 20:33","pubTimestamp":1741869181,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nFWN3PW12V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2519831653","title":"Institutional investors in Contineum Therapeutics, Inc. (NASDAQ:CTNM) have had a wonderful week after share price increased 24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2519831653","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519831653?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 20:20","pubTimestamp":1741868429,"startTime":"0","endTime":"0","summary":"Given the large stake in the stock by institutions, Contineum Therapeutics' stock price might be vulnerable to their trading decisions. A total of 11 investors have a majority stake in the company with 51% ownership. Ownership research along with  analyst forecasts data  help provide a good understanding of opportunities in a stock. Every investor in Contineum Therapeutics, Inc.  should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are institutions with 40% ownership. Put another way, the group faces the maximum upside potential .Clearly, institutional investors benefitted the most after the company's market cap rose by US$38m last week.Let's delve deeper into each type of owner of Contineum Therapeutics, beginning with the chart below.What Does The Institutional Ownership Tell Us About Contineum Therapeutics?The definition of an insider can differ slightly between different countries, but","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/institutional-investors-contineum-therapeutics-inc-122029483.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","PSQ","LU2095319765.USD","LU2210150020.SGD","LU2210149790.SGD","USJW.SI","NVIW.SI","NQmain","BK4585","MNQmain","CTNM","TQQQ","USAW.SI","BK4007","TSYW.SI","IE00B64PRP62.GBP","NDAQ","IE00BGHQF748.EUR","QID","IE00B3QW5Z07.USD","QLD","IE00BKPKM429.USD","SQQQ",".IXIC","BK4112"],"gpt_icon":1},{"id":"2517482621","title":"Contineum price target lowered to $16 from $32 at Baird","url":"https://stock-news.laohu8.com/highlight/detail?id=2517482621","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517482621?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 20:35","pubTimestamp":1741350950,"startTime":"0","endTime":"0","summary":"Baird lowered the firm’s price target on Contineum (CTNM) to $16 from $32 and keeps an Outperform rating on the shares. The firm said its Phase 2 r...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/contineum-price-target-lowered-to-16-from-32-at-baird?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/contineum-price-target-lowered-to-16-from-32-at-baird?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CTNM"],"gpt_icon":0},{"id":"2517115316","title":"Contineum Therapeutics Inc: Cash Runway Projected Through 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2517115316","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517115316?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 05:34","pubTimestamp":1741296874,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250306:nFWN3PP1MS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CTNM"],"gpt_icon":0},{"id":"2517135551","title":"Contineum Therapeutics Q4 2024 GAAP EPS $(0.56) Misses $(0.46) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2517135551","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517135551?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 05:12","pubTimestamp":1741295527,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.46) by 21.74 percent.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44179637/contineum-therapeutics-q4-2024-gaap-eps-0-56-misses-0-46-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTNM","LENZ"],"gpt_icon":0},{"id":"2517210118","title":"Press Release: Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2517210118","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517210118?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 05:05","pubTimestamp":1741295100,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones. - Topline data from PIPE-791 Phase 1b positron emission tomography  trial expected in the second quarter of 2025. - Topline data from PIPE-307 Phase 2 VISTA trial for the treatment of relapsing-remitting multiple sclerosis  anticipated in the second half of 2025. Contineum Therapeutics, Inc.  , a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology  indications, today reported its fourth-quarter 2024 financial results and affirmed its key clinical development milestones.\"2025 is shaping up to be a pivotal year, as we have several important clinical data readouts and trial initiations on the horizon,\" said Carmine Stengone, CEO, Contineum Therapeutics. \"We expect to be sponsoring up to six clinical trials during the course of the year, with key topline data from our PIPE-791 Phase 1b posi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BVYPNV92.GBP","IE00BFTCPJ56.SGD","BK4192","LU2129689514.USD","LU0792757196.USD","BK4007","IE0034235303.USD","LU0234570918.USD","LU1244550221.USD","LU1162221912.USD","JNJ","LU1061106388.HKD","LU2505996681.GBP","PET","LU1430594728.SGD","CTNM","LU1261432733.SGD","IE00B7SZLL34.SGD","LU0234572021.USD","IE0002141913.USD","LU2129689605.HKD","IE000M9KFDE8.USD","LU0345769631.USD","BK4585","LU0640476718.USD","IE00BVYPNW00.USD","LU0203347892.USD","LU1066053197.SGD","LU1244550494.USD","LU1244550577.SGD","LU0114720955.EUR","LU1914381329.SGD","IE0009355771.USD","LU0320765646.SGD","LU2592432038.USD","SG9999001440.SGD","LU1732800096.USD","LU0345769128.USD","LU0345770993.USD","LU2129689431.USD","BK4532","BK4504","IE00BSNM7G36.USD","LU1778281490.HKD","LU1267930813.SGD","LU2430703095.HKD","BK4550","LENZ","LU1196500208.SGD","BK4559"],"gpt_icon":0},{"id":"2517984500","title":"BRIEF-Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791","url":"https://stock-news.laohu8.com/highlight/detail?id=2517984500","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517984500?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 05:54","pubTimestamp":1741125286,"startTime":"0","endTime":"0","summary":"BRIEF-Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791March 4 (Reuters) - Contineum Therapeutics Inc CTNM.O:CONTINEUM THERAPEUTICS INITIATES PATIENT DOSING IN","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA6Z9DMN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2517989304","title":"Contineum Therapeutics Inc - Topline Data From Pipe-791 Phase 1B Trial Expected in Early 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2517989304","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517989304?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 05:05","pubTimestamp":1741122302,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA6Z9DMN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2517276986","title":"Contineum Therapeutics Initiates Patient Dosing in Phase 1B Chronic Pain Trial of Pipe-791","url":"https://stock-news.laohu8.com/highlight/detail?id=2517276986","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517276986?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 05:05","pubTimestamp":1741122302,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUA6Z9DMN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTNM","BK4007"],"gpt_icon":0},{"id":"2516561666","title":"Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2516561666","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516561666?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 05:05","pubTimestamp":1741035900,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 03, 2025----Contineum Therapeutics, Inc.  , a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology  indications, today announced that management is scheduled to present at the 2025 Leerink Partners Global Healthcare Conference on Tuesday, March 11th at 3:00 p.m. ET. An audio webcast of the presentation can be accessed on the Investors section of Contineum’s website. A webcast replay will also be available.Contineum Therapeutics  is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis, progressive multiple sclerosis and chronic pain, and PIPE-307 is a selective inhibitor of the M1 re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/contineum-therapeutics-present-2025-leerink-210500502.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTNM","LENZ","HCSG","BK4007","BK4137","BK4139"],"gpt_icon":0},{"id":"2502092045","title":"Contineum Therapeutics Price Target Maintained With a $31.00/Share by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2502092045","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502092045?lang=en_us&edition=full_marsco","pubTime":"2025-01-09 23:31","pubTimestamp":1736436660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CTNM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 09, 2025 10:31 ET (15:31 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","CTNM"],"gpt_icon":0},{"id":"2502013062","title":"Contineum Therapeutics, Inc. Class A (CTNM) Receives a Buy from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2502013062","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502013062?lang=en_us&edition=full_marsco","pubTime":"2025-01-09 19:55","pubTimestamp":1736423722,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams maintained a Buy rating on Contineum Therapeutics, Inc. Class A (CTNM – Research Report) yesterday and set a pri...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/contineum-therapeutics-inc-class-a-ctnm-receives-a-buy-from-rbc-capital?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/contineum-therapeutics-inc-class-a-ctnm-receives-a-buy-from-rbc-capital?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4207","BK4007","CTNM"],"gpt_icon":0},{"id":"2502081259","title":"Contineum Completes Enrollment in Trial for Relapsing-Remitting Multiple Sclerosis Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2502081259","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502081259?lang=en_us&edition=full_marsco","pubTime":"2025-01-09 06:37","pubTimestamp":1736375873,"startTime":"0","endTime":"0","summary":"Contineum Therapeutics  completed the enrollment of 168 patients in its phase 2 PIPE-307 VISTA trial for the treatment of relapsing-remitting multiple sclerosis.The trial is designed to assess safety and efficacy by evaluating multiple clinical and imaging endpoints sensitive to remyelination changes in RRMS patients, the company said. The last patient is expected to complete the trial by Q3.PIPE-307 is being developed under a global license and development agreement between Continuum and Janssen Pharmaceutica, a unit of Johnson & Johnson .","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["JNJ","LU0122379950.USD","LU0320765646.SGD","LU1430594728.SGD","LU1066053197.SGD","LU0114720955.EUR","BK4533","IE000M9KFDE8.USD","IE0034235303.USD","LU0345770993.USD","LU1059921491.USD","LU0640476718.USD","LU0345770308.USD","LU2089984988.USD","BK4592","CTNM","LU1244550221.USD","LU0058720904.USD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","BK4534","SG9999002232.USD","LU0795875086.SGD","LU1732800096.USD","LU1778281490.HKD","IE00B42XCP33.USD","LU0882574055.USD","SG9999001440.SGD","LU1221951129.SGD","LU1267930813.SGD","LU1057294990.SGD","LU0345769128.USD","LU1929549753.HKD","LU1074936037.SGD","LU0466842654.USD","LU1023059063.AUD","IE00B19Z3B42.SGD","LU1894683264.USD","LU1914381329.SGD","LU0234572021.USD","SG9999002224.SGD","LU1244550494.USD","LU1162221912.USD","LU0912757837.SGD","LU1718418525.SGD","LU0792757196.USD","IE00BVYPNV92.GBP","LU1221951046.USD","IE00BVYPNW00.USD","LU0098860793.USD"],"gpt_icon":0},{"id":"2502083502","title":"BRIEF-Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2502083502","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502083502?lang=en_us&edition=full_marsco","pubTime":"2025-01-09 05:12","pubTimestamp":1736370760,"startTime":"0","endTime":"0","summary":"BRIEF-Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)Jan 8 (Reuters) - Contineum Therapeutics Inc CTNM.O:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nTUA77JNBG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CTNM"],"gpt_icon":0},{"id":"2502508804","title":"Contineum Therapeutics Completes Enrollment in Phase 2 Pipe-307 Vista Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (Rrms)","url":"https://stock-news.laohu8.com/highlight/detail?id=2502508804","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502508804?lang=en_us&edition=full_marsco","pubTime":"2025-01-09 05:05","pubTimestamp":1736370301,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250108:nTUA77JNBG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CTNM","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.contineum-tx.com","stockEarnings":[{"period":"1week","weight":-0.1772},{"period":"1month","weight":-0.0192},{"period":"3month","weight":-0.5778},{"period":"6month","weight":-0.6394},{"period":"1year","weight":-0.6169},{"period":"ytd","weight":-0.5816}],"compareEarnings":[{"period":"1week","weight":-0.0536},{"period":"1month","weight":-0.0696},{"period":"3month","weight":-0.0933},{"period":"6month","weight":-0.0633},{"period":"1year","weight":0.0333},{"period":"ytd","weight":-0.0843}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"Contineum Therapeutics, INC.","nameEN":"Contineum Therapeutics, INC."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Contineum Therapeutics, INC.(CTNM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Contineum Therapeutics, INC.(CTNM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Contineum Therapeutics, INC.,CTNM,Contineum Therapeutics, INC.股票,Contineum Therapeutics, INC.股票老虎,Contineum Therapeutics, INC.股票老虎国际,Contineum Therapeutics, INC.行情,Contineum Therapeutics, INC.股票行情,Contineum Therapeutics, INC.股价,Contineum Therapeutics, INC.股市,Contineum Therapeutics, INC.股票价格,Contineum Therapeutics, INC.股票交易,Contineum Therapeutics, INC.股票购买,Contineum Therapeutics, INC.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Contineum Therapeutics, INC.(CTNM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Contineum Therapeutics, INC.(CTNM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction